Summary
Acquired amegakaryocytic thrombocytopenic purpura is a rare disease. Most reported patients did not respond to any therapeutical approach. Recently we observed a striking improvement of this disorder in a female patient shortly after therapy with danazol had been initiated. This observation and its possible implication for the treatment of amegakaryocytic thrombocytopenia are reported herein.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahn YS, Harrington WJ, Simon SR, Mylvaganam R, Pall LM, So AG (1983) Danazol for the treatment of idiopathic thrombocytopenic purpura. N Engl J Med 308: 1396–99
Hill W, Landgraf R (1985) Successful treatment of amegakaryocytic thrombocytopenic purpura with cyclosporine. N Engl J Med 312: 1060–61 (letter)
Hirsh EH, Vogler WR, McDonald TP, Stein SF (1980) Acquired hypomegakaryocytic thrombocytopenic purpura. Occurrence in a patient with absent thrombopoietic stimulating factor. Arch Int Med 140: 721–23
Hoffman R, Bruno E, Elwell J, Mazur E, Gewirtz AM, Dekker P, Denes AE (1982) Acquired amegakaryocytic thrombocytopenic purpura: a syndrome of diverse etiologies. Blood 60: 1173–78
Stoll DB, Blum S, Pasquale D, Murphy S (1981) Thrombocytopenia with decreased megakaryocytes. Evaluation and prognosis. Ann Int Med 94: 170–75
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kayser, W., Euler, H.H., Schmitz, N. et al. Danazol in acquired amegakaryocytic thrombocytopenic purpura: A case report. Blut 51, 401–404 (1985). https://doi.org/10.1007/BF00320726
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00320726